Blog
Donec sollicitudin molestie malesuada.
Follow:
Press Release: ColoHealth Blood Test Offers a Simpler First Step in Colorectal Cancer Screening–Now Direct-to-Consumer
New Day Diagnostics today announced the launch of ColoHealth™, a groundbreaking blood test for colorectal cancer screening is now accessible to adults aged 50+ who are at average risk. This test offers a non-invasive alternative for individuals who are unwilling or...
Hepion Pharmaceuticals, New Day Diagnostics execute binding letter of intent
We’re honored to be featured in publications near and far, but there’s something especially meaningful about being recognized by our local and regional community. Thank you to Teknovation for helping share the news of our latest opportunity. Be sure to explore more of...
Press Release: Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other...
We’ve Been Busy, and the Press Has Noticed!
The past few months have been an exciting time for all of us at New Day Diagnostics. Since launching ColoHealth™, our blood-based colorectal cancer screening test, we've been honored to see our story featured in over 200 independent news articles across the country. ...
Press Release: ColoHealth™ Launches Nationwide to Expand Access to Colorectal Cancer Screening
ColoHealth is a blood test that detects alterations in DNA associated with colorectal cancer. It is not meant to replace a colonoscopy, but can inform patients who are unable or unwilling to do other forms of screening about their need for a colonoscopy.
Knoxville lab launches blood test for colorectal cancer screening across US: ‘Life mission’
By Daniel DassowKnoxville News SentinelKnoxville-based biotech company New Day Diagnostics launched its blood test screening for colorectal cancer nationwide after completing a year-long local pilot that helped patients reduce their risk for the deadly disease. Its...
Understanding CLIA and Its Crucial Role in Diagnostic Development
Clinical Laboratory Improvement Amendments (CLIA) is a set of regulations established by the United States government to ensure the quality, accuracy, and reliability of clinical laboratory testing. These regulations are vital for diagnostic development, as they...
Development of an algorithm combining blood-based biomarkers, fecal immunochemical test, and age for population-based colorectal cancer screening
Mathias M. Petersen, Jakob Kleif, Jason Liggett, Morten Rasmussen, Lars N. Jørgensen, Jesper Vilandt, Jakob B. Seidelin, Carla M.T. Beertsen, Annemieke C. Heijboer, Claudia Jaensch, Peter Bondeven, Kåre A. Gotschalck, Uffe Schou Løve, Susan H. Gawel, Berit Andersen,...
Press Release: Augurex and New Day Diagnostics Collaborate to Launch SPINEstat™, RevolutionizingEarly Diagnosis and Management of Ankylosing Spondylitis
By Augurex at www.augurex.com Vancouver, BC, Canada and Knoxville, TN, USA, 30 May 2024 – Augurex and New Day Diagnostics are excited to announce their collaboration to launch SPINEstat™, a first-of-its-kind multiplex biomarker assay that will transform the management...
Contact us
Call Us
Email Us
Our Location
5678 Extra Rd. #123
San Francisco, CA 96120